In another study, the effectiveness of the monoclonal anti-programmed-death-1 (PD-1) antibody drug, Nivolumab [53], was examined in research including 82 patients with metastatic renal cell carcinoma (RCC) and 79 patients with advanced melanoma [54]. Here, PDCD1 is linked to melanoma.